Sievers Chelsie K, Leystra Alyssa A, Clipson Linda, Dove William F, Halberg Richard B
McArdle Laboratory for Cancer Research, Department of Oncology, University of Wisconsin-Madison, Madison, Wisconsin. Department of Medicine, University of Wisconsin School of Medicine and Public Health, Madison, Wisconsin.
McArdle Laboratory for Cancer Research, Department of Oncology, University of Wisconsin-Madison, Madison, Wisconsin.
Cancer Prev Res (Phila). 2016 Aug;9(8):638-41. doi: 10.1158/1940-6207.CAPR-16-0096. Epub 2016 May 19.
Advances in DNA sequencing have created new opportunities to better understand the biology of cancers. Attention is currently focused on precision medicine: does a cancer carry a mutation that is targetable with already available drugs? But, the timing at which multiple, targetable mutations arise during the adenoma to carcinoma sequence remains unresolved. Borras and colleagues identified mutations and allelic imbalance in at-risk mucosa and early polyps in the human colon. Their analyses indicate that mutations in key genes can arise quite early during tumorigenesis and that polyps are often multiclonal with at least two clones. These results are consistent with the "Big Bang" model of tumorigenesis, which postulates that intratumoral heterogeneity is a consequence of a mutational burst in the first few cell divisions following initiation that drives divergence from a single founder with unique but related clones coevolving. Emerging questions center around the ancestry of the tumor and impact of early intratumoral heterogeneity on tumor establishment, growth, progression, and most importantly, response to therapeutic intervention. Additional sequencing studies in which samples, especially at-risk tissue and premalignant neoplasms, are analyzed from animal models and humans will further our understanding of tumorigenesis and lead to more effective strategies for prevention and treatment. Cancer Prev Res; 9(8); 638-41. ©2016 AACRSee related article by Borras, et al., Cancer Prev Res 2016;9(6):417-427.
DNA测序技术的进步为更好地理解癌症生物学创造了新机遇。目前,人们的注意力集中在精准医学上:癌症是否携带可被现有药物靶向的突变?但是,在腺瘤到癌的进程中多个可靶向突变出现的时间仍未明确。博拉斯及其同事在人类结肠的癌前黏膜和早期息肉中发现了突变和等位基因失衡。他们的分析表明,关键基因的突变可能在肿瘤发生的早期就出现,而且息肉通常是多克隆的,至少有两个克隆。这些结果与肿瘤发生的“大爆炸”模型一致,该模型假定肿瘤内异质性是起始后最初几次细胞分裂中突变爆发的结果,这种爆发促使从单个始祖细胞分化出具有独特但相关的共同进化克隆。新出现的问题集中在肿瘤的起源以及早期肿瘤内异质性对肿瘤形成、生长、进展,最重要的是对治疗干预反应的影响。对动物模型和人类的样本,尤其是癌前组织和癌前肿瘤进行分析的更多测序研究,将加深我们对肿瘤发生的理解,并带来更有效的预防和治疗策略。《癌症预防研究》;9(8);638 - 41。©2016美国癌症研究协会。见博拉斯等人的相关文章,《癌症预防研究》2016;9(6):417 - 427。